| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 15.74% | JP Morgan | $67 → $70 | Maintains | Overweight |
| 11/07/2023 | -10.71% | Morgan Stanley | $50 → $54 | Maintains | Equal-Weight |
| 10/13/2023 | -17.33% | Morgan Stanley | $81 → $50 | Maintains | Equal-Weight |
| 08/04/2023 | 81.88% | TD Cowen | $95 → $110 | Maintains | Outperform |
| 07/19/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 05/18/2023 | 42.2% | Canaccord Genuity | $91 → $86 | Maintains | Buy |
| 05/03/2023 | 33.93% | Morgan Stanley | $74 → $81 | Maintains | Equal-Weight |
| 05/02/2023 | 48.81% | Oppenheimer | $85 → $90 | Maintains | Outperform |
| 02/23/2023 | 24.01% | Cowen & Co. | $70 → $75 | Maintains | Outperform |
| 02/23/2023 | 28.97% | Canaccord Genuity | $68 → $78 | Maintains | Buy |
| 02/23/2023 | 33.93% | JP Morgan | $67 → $81 | Maintains | Overweight |
| 02/23/2023 | 40.54% | Oppenheimer | $55 → $85 | Maintains | Outperform |
| 02/23/2023 | 22.35% | Morgan Stanley | $63 → $74 | Maintains | Equal-Weight |
| 01/06/2023 | 4.17% | Morgan Stanley | $54 → $63 | Maintains | Equal-Weight |
| 11/04/2022 | -10.71% | Morgan Stanley | $45 → $54 | Maintains | Equal-Weight |
| 10/11/2022 | -25.6% | Morgan Stanley | $37 → $45 | Maintains | Equal-Weight |
| 08/03/2022 | -38.82% | Morgan Stanley | $34 → $37 | Maintains | Equal-Weight |
| 08/02/2022 | -25.6% | Oppenheimer | $40 → $45 | Maintains | Outperform |
| 08/02/2022 | -20.63% | JP Morgan | $26 → $48 | Upgrades | Neutral → Overweight |
| 07/26/2022 | -25.6% | Cowen & Co. | $39 → $45 | Maintains | Outperform |
| 06/29/2022 | -43.78% | Morgan Stanley | $25 → $34 | Maintains | Equal-Weight |
| 06/28/2022 | -35.52% | Cowen & Co. | $35 → $39 | Maintains | Outperform |
| 05/04/2022 | -58.66% | Morgan Stanley | $15 → $25 | Maintains | Equal-Weight |
| 03/17/2022 | -35.52% | Canaccord Genuity | $38 → $39 | Maintains | Buy |
| 02/25/2022 | -75.2% | Morgan Stanley | $22 → $15 | Maintains | Equal-Weight |
| 01/07/2022 | -63.62% | Morgan Stanley | $33 → $22 | Maintains | Equal-Weight |
| 05/05/2021 | -42.13% | Morgan Stanley | $38 → $35 | Maintains | Equal-Weight |
| 03/04/2021 | -37.17% | Morgan Stanley | $16 → $38 | Maintains | Equal-Weight |
| 11/06/2020 | -73.54% | Morgan Stanley | $18 → $16 | Maintains | Equal-Weight |
| 10/08/2020 | -75.2% | JP Morgan | → $15 | Downgrades | Overweight → Neutral |
| 08/07/2020 | -70.24% | Morgan Stanley | $15 → $18 | Maintains | Equal-Weight |
| 08/06/2020 | -66.93% | Canaccord Genuity | $19 → $20 | Maintains | Buy |
| 04/14/2020 | -68.58% | Canaccord Genuity | $20 → $19 | Maintains | Buy |
| 04/07/2020 | -58.66% | Oppenheimer | → $25 | Initiates Coverage On | → Outperform |
| 03/04/2020 | -73.54% | Morgan Stanley | $22 → $16 | Maintains | Equal-Weight |
| 11/07/2019 | -53.7% | Cowen & Co. | $40 → $28 | Maintains | Outperform |
| 05/28/2019 | -33.86% | Cowen & Co. | → $40 | Initiates Coverage On | → Outperform |
| 05/28/2019 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 05/28/2019 | -38.82% | Canaccord Genuity | → $37 | Initiates Coverage On | → Buy |
| 05/28/2019 | -43.78% | JP Morgan | → $34 | Initiates Coverage On | → Overweight |
What is the target price for TransMedics Gr (TMDX)?
The latest price target for TransMedics Gr (NASDAQ: TMDX) was reported by JP Morgan on November 7, 2023. The analyst firm set a price target for $70.00 expecting TMDX to rise to within 12 months (a possible 15.74% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TransMedics Gr (TMDX)?
The latest analyst rating for TransMedics Gr (NASDAQ: TMDX) was provided by JP Morgan, and TransMedics Gr maintained their overweight rating.
When is the next analyst rating going to be posted or updated for TransMedics Gr (TMDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransMedics Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransMedics Gr was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating TransMedics Gr (TMDX) correct?
While ratings are subjective and will change, the latest TransMedics Gr (TMDX) rating was a maintained with a price target of $67.00 to $70.00. The current price TransMedics Gr (TMDX) is trading at is $60.48, which is out of the analyst's predicted range.